e5361f4b-702f-4404-aa03-1cb37ea109b1
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.600
- MYC_TARGETS_V2+0.600
- G2M_CHECKPOINT+0.500
- MYC_TARGETS_V1+0.500
- FATTY_ACID_METABOLISM+0.400
- MTORC1_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- CHOLESTEROL_HOMEOSTASIS+0.300
- DNA_REPAIR+0.300
- ESTROGEN_RESPONSE_LATE+0.300
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.500
- UV_RESPONSE_DN-0.300
- ALLOGRAFT_REJECTION-0.200
- ANGIOGENESIS-0.200
- IL6_JAK_STAT3_SIGNALING-0.200
- KRAS_SIGNALING_UP-0.200
- TGF_BETA_SIGNALING-0.200
- WNT_BETA_CATENIN_SIGNALING-0.200
- APICAL_JUNCTION-0.100
- HYPOXIA-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-18-3412-01A-01R-0980-07 | — | cohortSQ2 | 0.877 |
| 2 | SRR8518397 | — | E | 0.868 |
| 3 | fddf611e-f586-49e1-9ee8-8ac853accb9e | — | — | 0.864 |
| 4 | TCGA-E9-A1RB-01A-11R-A157-07 | — | C | 0.838 |
| 5 | f20785b9-991d-4b87-8ba7-ca32373f1996 | — | — | 0.838 |
| 6 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.833 |
| 7 | SRR1516095 | — | — | 0.827 |
| 8 | 8c76ce45-f110-4f6a-b413-13a1a1aeddef | — | — | 0.827 |
| 9 | BSR_12_0070_A1_S79 | — | C | 0.823 |
| 10 | TCGA-39-5036-01A-01R-1443-07 | — | cohortSQ2 | 0.819 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.600 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.500 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.500 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.300 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.200 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |